Antithrombin Market - Size, Share, Outlook, 2026

Antithrombin is a protein present in blood that inhibits blood clotting by inactivating thrombin. Antithrombin is produced by liver and consists of 432 amino acids. There are two major reasons of antithrombin deficiency, which include acquired antithrombin deficiency caused due to other diseases such as nephrotic syndrome, liver failure, severe trauma, and metastatic tumors and inherited antithrombin deficiency caused due to a genetic mutation or abnormality. According to the NCBI (National Center for Biotechnology Information), inherited antithrombin deficiency is a rarely occurring deficiency and only a maximum of 0.2% of the global population has this deficiency. One of the most popular drugs for the treatment of antithrombin deficiency available in the market is ATryn, which was developed by rEVO Biologics and received the U.S. Food and Drug Administration (FDA) approval in 2009. Antithrombin shows synergistic activity with heparin that enhances the antithrombin binding with Thrombin (factor II a) and Factor Xa. Antithrombin III blood test is required to measure the amount of deficiency of antithrombin that is causing the blood to clot more easily than normal.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/2018

Antithrombin Market – Market Dynamics

Increasing incidence of coagulation disorders, open heart surgeries, and extracorporeal circulation during hemodialysis is augmenting growth of antithrombin market. According to the Centers for Disease Control and Prevention (CDC), 2015, around 900,000 people is affected from venous thromboembolism every year in the U.S. Furthermore, 5 to 8% of the U.S. population has increased risk of suffering from thrombosis due to one of the several genetic risk factors known as inherited thrombophilia.

Therapeutic drug pipeline or advancements in drug administering technology is also expected to fuel growth of antithrombin market. For instance, Fitusiran (ALN-AT3), developed by Alnylam Pharmaceuticals, Inc., is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT). This therapeutic that can be used for the treatment of hemophilia and rare bleeding disorders (RBDs) is in late stage (Phase 2-phase 3) clinical trial. Moreover, GTC Biotherapeutics, Inc.’s product called as ATryn Antithrombin (Recombinant), derived from human blood donors, is used for hereditary antithrombin deficiency and it recently got market approval in the U.S., thereby significantly contributing to the growth of antithrombin market. Therefore, introduction of new types of antithrombin products with different indication over the forecast period is expected to fuel growth of the global antithrombin market. Furthermore, increasing use of antithrombin in combination with heparin is likely to support the growth of antithrombin market. For instance, heparin resistance in cardiac surgery is likely to create opportunities for use of antithrombin products in anticoagulation therapy.

However, increasing regulations on animal testing have impeded a number of healthcare companies from manufacturing new drugs, thereby restraining the market growth.

To get detailed table of content (ToC), please click - https://www.coherentmarketinsights.com/ongoing-insight/toc/2018

Antithrombin Market - Regional Analysis

On the basis of region, the global antithrombin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to gain significant traction in the global antithrombin market, followed by Europe, owing to adoption of robust developed technologies and antithrombin therapies, and high awareness and increasing regulatory approval of drugs in these regions.

Moreover, improving healthcare infrastructure in emerging economies such as China and India, and increasing research and development activities are contributing towards the growth of antithrombin market in Asia Pacific region. For instance, in 2016, China Biologic Products, Inc.’s subsidiary, Shandong Taibang Biological Products Co. Ltd., recently obtained approval from the China Food and Drug Administration (CFDA) to begin human clinical trials using its Human Antithrombin III (ATIII) product for the treatment of hereditary and acquired ATIII deficiency which are more prone during surgical or obstetrical procedures, and treatment of thromboembolism.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/antithrombin-market-2018

Antithrombin Market – Competitive Landscape

The antithrombin market is characterized by the presence of few established players. There is stiff competition in the market, as these few players occupy major market share. Key players operating in the global antithrombin market include Grifols, Shire Plc., rEVO Biologics Inc., CSL Limited, Kedrion S.p.A, Lee Bisolutions, Scripps Laboratories Inc., GTC Biotherapeutics, Inc.’s, Green Cross Corp., and BDI Pharma.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Blog: https://globalresearchtrends.blogspot.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.